πŸ‡ΊπŸ‡Έ FDA
Patent

US 12161643

Stable formulations of SHR0302

granted A61KA61K31/519A61K31/52

Quick answer

US patent 12161643 (Stable formulations of SHR0302) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCUTIS BIOTHERAPEUTICS, INC.
Grant date
Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/519, A61K31/52, A61K47/08, A61K47/12